Crucial Data Solutions, Inc. (CDS), a technology provider focused on data collection and clinical trial management, has announced several updates in celebration of its tenth anniversary, including the company’s latest technological development, TrialKit AI, a machine-learning API.
“With more than 10,000 users conducting hundreds of clinical device and drug trials across all phases, CDS has been a quiet industry leader for many years,” said Jeff Rogers, President of Crucial Data Solutions. “As we continue to invest in delivering the latest technology for better system performance, unlimited scalability, and an ever-improving user experience, we are excited to introduce TrialKit AI to the market/industry."
TrialKit AI is able to parse structured and unstructured data from any EHR platform without any need for integration or mapping from the EHR (electronic health record) platform. Those parsed data are then programmatically mapped and populated directly into forms (CRFs) within TrialKit EDC (previously Clinical Studio), or any other structured database.
When CDS launched TrialKit in 2016 it was a native mobile app empowering users to accomplish all data collection and study management tasks on any compatible iOS or Android device. The app complemented the capabilities of Clinical Studio, CDS’ flagship web-based platform for data collection and study management, and enabled true virtual trials. In addition to launching TrialKit AI, CDS is consolidating Clinical Studio and TrialKit mobile under the same umbrella and brand: TrialKit. This consolidation represents the unified nature of the web and mobile interfaces and the single, shared back-end database in the cloud.
The rebranding efforts include a comprehensive redesign of the CDS website, logos, graphics, and messaging. These updated brand assets more clearly convey TrialKit’s end-to-end, web- and mobile-based capabilities for collecting and managing data through the modular components including EDC, CTMS, ePRO/eCOA, eConsent, randomization, inventory/supply management, medical coding, lab management, adjudication, and reporting. With the addition of TrialKit AI, research professionals now have the unprecedented ability to utilize unstructured data for clinical trials.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
Vabysmo Shows Significant Vision Improvement for Diabetic Macular Edema in Underrepresented Patients
October 22nd 2024Phase IV ELEVATUM trial results show that one year of treatment with Vabysmo significantly improved vision in underrepresented racial and ethnic groups with diabetic macular edema, supporting the drug's efficacy and safety across diverse populations.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Clesrovimab Shows Significant Reduction in RSV Infections, Hospitalizations in Infants
October 18th 2024Merck's investigational monoclonal antibody, clesrovimab, shows significant efficacy in reducing respiratory syncytial virus-related infections and hospitalizations in infants, with a favorable safety profile.